1999
DOI: 10.1002/chin.199920293
|View full text |Cite
|
Sign up to set email alerts
|

ChemInform Abstract: α‐Gal Oligosaccharides: Chemistry and Potential Biomedical Application

Abstract: organic chemistry, review organic chemistry, review Z 0200 20 -293 α-Gal Oligosaccharides: Chemistry and Potential Biomedical Application -[90 refs.]. -(JANCZUK, A.; LI, J.; ZHANG, W.; CHEN, X.; CHEN, Y.; FANG, J.; WANG, J.; WANG, P. G.; Curr. Med. Chem. 6 (1999) 2, 155-164; Dep. Chem., Wayne State Univ., Detroit, MI 48202, USA; EN)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2008
2008
2008
2008

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…The α-Gal epitopes are present in both glycoproteins and glycolipids, and have carbohydrate structures that contain Galα1-3Gal terminus [1]. To overcome HAR during xenotransplantation, various approaches have been attempted to eliminate the α-Gal epitope in the pig donor organ, including using α1,3-galacosyltransferase knock-out or knock-down methods [4,5], capping the α-Gal epitope using fucosyltransferase knock-in method [6] or in xenograft recipient regulation of B cell or T cell response to α-Gal epitopes, suppression of complement activation [7] and removal of anti-Gal antibodies in the serum of xenograft recipient through an α-Gal affinity column [8][9][10][11]. Among these approaches, depleting the recipient's anti-α-Gal antibody (anti-Gal Ab) using α-Gal immobilized columns has the highest potential for early stage trials.…”
Section: Introductionmentioning
confidence: 99%
“…The α-Gal epitopes are present in both glycoproteins and glycolipids, and have carbohydrate structures that contain Galα1-3Gal terminus [1]. To overcome HAR during xenotransplantation, various approaches have been attempted to eliminate the α-Gal epitope in the pig donor organ, including using α1,3-galacosyltransferase knock-out or knock-down methods [4,5], capping the α-Gal epitope using fucosyltransferase knock-in method [6] or in xenograft recipient regulation of B cell or T cell response to α-Gal epitopes, suppression of complement activation [7] and removal of anti-Gal antibodies in the serum of xenograft recipient through an α-Gal affinity column [8][9][10][11]. Among these approaches, depleting the recipient's anti-α-Gal antibody (anti-Gal Ab) using α-Gal immobilized columns has the highest potential for early stage trials.…”
Section: Introductionmentioning
confidence: 99%